No Data
No Data
ST BALLING: 2024 Semi-Annual Report
ST Bering: 2024 Semi-Annual Report Summary
Both Individual Investors Who Control a Good Portion of Guizhou Bailing Group Pharmaceutical Co., Ltd. (SZSE:002424) Along With Institutions Must Be Dismayed After Last Week's 7.7% Decrease
Special treat Bai Ling (002424.SZ): has initiated the application procedure for the new drug IND of Tangning Tongluo.
On August 16th, Gelonhui reported that Special Treat Baoling (002424.SZ) has initiated the application process for IND of Tongning New Drug. After obtaining phased progress, the company will fulfill its disclosure obligations in a timely manner.
As of August 9th, 2024, the total number of shareholders of ST Bai Ling (002424.SZ) was 98,063.
On August 16th, Gelunhui reported that as of August 9th, 2024, the total number of shareholders in ST Bailing (002424.SZ) was 98,063 on the investor interaction platform.
Special treat Bailin (002424.SZ): The main source of revenue is Tibet Jinling and Big Health Company.
On August 7, 2024, ST Baoling (002424.SZ) accepted a specific object survey on "what are the parts included in commerce?" The company responded that commercial revenue is mainly from Tibet Special Treat and Pharmaceutical Commerce. Tibet Special Treat is a sales channel for OTC products and sales of OEM products. Pharmaceutical Commerce mainly sells and distributes pharmaceuticals in the local market of Anshun.
No Data
No Data